Arcturus Therapeutics (ARCT) Tops Q4 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
March 7, 2024 4:01 PM ESTKostaive® anticipated to launch in Japan this year
ARCT-032 remains on track for Phase 1b interim data in Q2
ARCT-810 remains on track for Phase 2 interim data by the end of Q2
ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated
New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea
Cash runway extended to Q1 2027
Investor conference call at 4:30 p.m. ET today
SAN DIEGO--(BUSINESS WIRE)-- Arcturus... More
